All the funding deals in the cell therapy market

We tracked 72 cell therapy funding deals from 2023 to early 2026, covering a wide range of approaches from CAR-T and TCR-T to iPSC-derived therapies and in vivo cell engineering.

We refresh this page every quarter to keep it current with the latest cell therapy fundraising activity.

And if you want to better understand this new industry, you should get our beautiful slides covering the cell therapy market.

In our cell therapy market deck, we show you long-term trends so you can make better decisions

Summary table of the funding deals for the cell therapy market since 2023

We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.

We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.

We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.

We focused exclusively on pure players, defined as companies with at least 70-80% of their business directly tied to the cell therapy market.

Our analysis has been done at a global level with a minimum funding threshold of $300k.

You can also read our detailed analysis to understand how funding activity in the cell therapy market has evolved recently.

If you want a longer-term view, we also have a study of how funding activity in the cell therapy market has changed over the years.

Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the cell therapy market.

In our cell therapy market deck, we will give you useful market maps and grids

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.